Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syntex ganciclovir NDA

Executive Summary

Scheduled July 13 meeting of FDA's Anti-Infective Drugs Advisory Cmte. postponed at agency's request to allow further review of Syntex NDA and analysis of Burroughs Wellcome data. B-W recently discontinued its IND for ganciclovir (for cytomegalovirus in immune-compromised patients), and Syntex assumed responsibility to provide the drug to former B-W patients under the Syntex IND and compassionate-use program. Discussion of the drug has not officially been rescheduled, but the committee's next meeting is Oct. 26-27.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel